China Adherence Through Technology Study (CATS)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
FHI 360
Guangxi Center for Disease Control and Prevention
Dimagi Inc.
Massachusetts General Hospital
Information provided by (Responsible Party):
Lora Sabin, Boston University
ClinicalTrials.gov Identifier:
NCT01722552
First received: November 3, 2012
Last updated: April 19, 2013
Last verified: April 2013

November 3, 2012
April 19, 2013
November 2012
April 2014   (final data collection date for primary outcome measure)
Difference in proportion of subjects who achieve >/= 95% adherence [ Time Frame: Measured at 6 months after start of intervention ] [ Designated as safety issue: No ]
Subjects will participate in the 6-month real-time feedback intervention. Comparison patients will continue to be monitored by Wisepill, but they will remain blinded to the adherence information generated by the Wisepill devices, as will their care providers.
Same as current
Complete list of historical versions of study NCT01722552 on ClinicalTrials.gov Archive Site
Proportion of subjects who achieve >/= 95% cumulative adherence over entire 6 months of intervention period [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Subjects will participate in the 6-month real-time feedback intervention. Comparison patients will continue to be monitored by Wisepill, but they will remain blinded to the adherence information generated by the Wisepill devices, as will their care providers.
Same as current
Not Provided
Not Provided
 
China Adherence Through Technology Study
China Adherence Through Technology Study

The CATS project is designed to increase understanding of interventions that are feasible and effective in helping injection drug users (IDU) or other patients at high risk of poor medication adherence who are HIV-positive to maintain a high ART adherence. The study will involve: assessing the feasibility and acceptability of using real-time feedback, a wireless technology-updated adaptation of an approach the investigators found to be feasible and effective in China, to promote ART adherence among Chinese patients, including IDU; generating preliminary effectiveness data of real-time feedback on adherence, CD4 count, and HIV viral load; and identifying the factors that explain how real-time feedback influences intervention success or failure.

The specific aims of the study are:

SA1: Determine the feasibility and acceptability of using real-time feedback, a wireless technology-updated adaptation of an approach we found to be feasible and effective in China, to promote ART adherence among Chinese patients. The investigators will conduct a pilot RCT of the real-time feedback intervention among Chinese patients in order to assess its feasibility and acceptability in this population.

SA2: Generate preliminary effectiveness data of real-time feedback on adherence, CD4 count, and HIV viral load. The RCT will allow the researchers to generate rigorous estimates of effect sizes on these important endpoints.

SA3: Describe the factors that explain how real-time feedback influences intervention success or failure. The investigators will use a quantitative-qualitative mixed-methods research approach to explore how the intervention influences the experience of adherence support in this patient population.

The investigators will implement CATS over 2.5 years by implementing a randomized controlled trial to assess real-time feedback, an intervention that utilizes wireless technology via an electronic pill container device ('Wisepill'), and investigating the mechanisms by which the intervention operates using quantitative and qualitative research methods. 120 patients will be enrolled in a HIV clinic in Nanning, capital of Guangxi province, a border province with high rates of HIV and IDU. Enrolled patients will be randomized to intervention vs. comparison group for the 6-month intervention. The study will follow all patients for an additional 3 months to determine sustainability of intervention impact. In addition to adherence and clinical data, quantitative and qualitative data will be collected using survey instruments, focus groups, and in-depth interviews. Analysis of these data will enable achievement of the specific aims and contribute to the scientific evidence base on effective approaches to promoting ART adherence among IDU and other patients.

Interventional
Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Medication Adherence
Behavioral: adherence feedback
Experimental: adherence feedback
Intervention subjects will receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time (as indicated by lack of a Wisepill opening). They will then participate in monthly interactive counseling sessions using summaries of their previous month's behavior. Patients whose mean adherence in the previous month was <95% will be required to have a counseling session, while those with higher adherence will be given the option to have a counseling session.
Intervention: Behavioral: adherence feedback
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
120
April 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients who are 18 years of age and above, currently on ART or about to begin ART at the Guangxi CDC clinic, deemed at risk for poor adherence either by patients or medical staff, own a cell phone, and provide written consent.

Exclusion Criteria:

  • Persons who do not speak Mandarin Chinese or who have mental health issues such that they cannot provide written informed consent will not be allowed to participate.
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States,   China
 
NCT01722552
1R34DA032423 - 01A1
No
Lora Sabin, Boston University
Boston University
  • FHI 360
  • Guangxi Center for Disease Control and Prevention
  • Dimagi Inc.
  • Massachusetts General Hospital
Principal Investigator: Lora Sabin, PhD Boston University Center for Global Health and Development
Boston University
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP